Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ATHX > SEC Filings for ATHX > Form 8-K on 13-Jan-2014All Recent SEC Filings

Show all filings for ATHERSYS, INC / NEW

Form 8-K for ATHERSYS, INC / NEW


13-Jan-2014

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

Athersys, Inc. (the "Company") is filing herewith the following exhibits to its Registration Statement on Form S-3 (Registration No. 185991):

1. Placement Agency Agreement, dated as of January 10, 2014 between the Company and Maxim Group, LLC.

2. Form of Warrant; and

3. Form of Securities Purchase Agreement.

On January 10, 2014, the Company entered into a Placement Agency Agreement (the "Placement Agreement") with Maxim Group, LLC ("Maxim Group") pursuant to which Maxim Group agreed to use its reasonable best efforts to arrange for the sale of up to (i) 5,000,000 shares of the Company's common stock, $0.001 par value per share (the "Common Stock") and (ii) warrants to purchase up to an additional 1,500,000 shares of Common Stock, which shall be immediately exercisable at any time and from time to time upon closing (the "Warrants") at an exercise price of $4.50 per share, in a registered direct offering (the "Offering"). The sale of the Common Stock and Warrants is being made pursuant to Securities Purchase Agreements between the Company and each investor party thereto. The Common Stock and the Warrants will be sold in multiples of a fixed combination consisting of
(i) one share of Common Stock and (ii) one Warrant to purchase 0.30 shares of Common Stock. Each fixed combination will be sold to investors at a price of $4.10. The warrants will be exercisable until July 15, 2016.

The Company has agreed to pay Maxim Group a fee equal to 7.0% of the gross proceeds received in the Offering (the "Placement Fee").

The net proceeds to the Company from the Offering, after deducting Maxim Group's fees and the Company's estimated offering expenses, are expected to be approximately $18.7 million. The Offering is expected to close on or about January 15, 2014, subject to the satisfaction of customary closing conditions. The Company intends to use these net proceeds for working capital and general corporate purposes, including the funding of its ongoing and planned clinical trials, and potential expansion of certain clinical trials to take advantage of emerging international regulatory initiatives designed to accelerate the development and commercialization of regenerative medicine therapies, and certain process development and manufacturing initiatives.

A copy of the Placement Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference, and the description of the material terms of the Placement Agreement is qualified in its entirety by reference to such exhibit. A copy of the form of Securities Purchase Agreement and the form of the Warrants are filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The descriptions of the material terms of the Securities Purchase Agreements and the Warrants are qualified in their entirety by reference to such exhibits.




Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.                              Exhibit Description

1.1               Placement Agency Agreement, dated as of January 10, 2014, between
                  the Company and Maxim Group, LLC.

4.1               Form of Warrant.

10.1              Form of Securities Purchase Agreement.


  Add ATHX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ATHX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.